Accueil
Envoyer
Imprimer
Partager
VI Partners’ mission is to support promising early-stage healthcare and technology startups in Switzerland with a historical focus on university spin-offs. Since 2001, Venture Incubator has invested CHF 202 million in 48 companies. 28 companies were sold for a total consideration of CHF 240 million. The investments in the portfolio companies created over 1,500 highly qualified jobs in Switzerland alone.
This success story gets to another impressive chapter: During the last two months, VI Partners managed to successfully sell two participations:
• Nexthink: The shares owned by Venture Incubator were acquired in June 2019 in a secondary transaction by existing investors in the company.
• AMAL: The entire company was acquired by research-driven pharmaceutical company Boehringer Ingelheim for up to € 420 million in July 2019.
With the sales and transfers of the two companies, the fund realizes proceeds of up to CHF 105 million, depending on achievement of certain milestones. These results and developments demonstrate the commitment that Venture Incubator and VI Partners have to create meaningful companies in Switzerland.
Nexthink: 460 employees and 1,000 customers worldwide
Nexthink was launched as a result of a research project conducted at the prestigious Ecole Polytechnique Fédérale de Lausanne (EPFL) by Pedro Bados, Patrick Herzog and Vincent Bieri. The company has become the worldwide leader in the monitoring of employee experience for enterprises. Venture Incubator was the first institutional investor and the fund has been an active shareholder since the in initial investment. Today, Nexthink serves 1,000 customers worldwide (reaching over 7 million users), is growing 80% per annum and has attracted $130 million in financing.
Pedro Bados, co- founder and CEO of Nexthink, says: “It’s been a great experience with Alain and VI Partners who have supported Nexthink from the early stage until becoming a world-wide company. I would highly recommend any entrepreneur in Switzerland to consider them for their next venture.”
Alain Nicod, Managing Partner of VI Partners, says: «I am thankful to Pedro Bados, Patrick Herzog and Vincent Bieri that they have welcomed us as their first institutional investor in their newly born Nexthink SA. The road from the 5-person team I met then, to today’s business with 460 employees serving more than 7 million devices connected to their service, was incredibly exciting. I am particularly proud of having contributed to support the company’s growth not only with the initial money, but also with contacts, prospective customers, ideas, key management members and investors.»
AMAL: A unique technology platform to treat life-threatening diseases
AMAL was founded by Madiha Derouazi in 2012 as a spin-off from the University of Geneva, Switzerland. The start-up got financial backing from a syndicate of both corporate and institutional investors. AMAL’s proprietary technology platform KISIMA enables the assembly of three functional components into one patented fusion protein used as a vaccine: First, a proprietary cell-penetrating peptide for antigen delivery; second, a proprietary toll-like receptor (TLR) peptide agonist as an adjuvant; and third, a multi-antigenic cargo that can be tailored for specific tumors and other indications.
Madiha Derouazi, founder and CEO of AMAL, says: «I would like to warmly and sincerely thank VI Partners for their support to AMAL since our Series A investment back in March 2016. Their trust and commitment to AMAL as well as Diego Braguglia’s personal dedication and involvement have been instrumental to AMAL's success all along our journey which ends with this fantastic transaction."
Diego Braguglia, Managing Partner of VI Partners, comments: «I have rarely seen a company operating as cash efficient as AMAL. Madiha and her team can look back on an incredible journey, from bench to patient's bed sides in an unbelievably short period of time. I am deeply grateful to have been able to be part of this team and contribute along with the Venture Incubator investment to help and support patients suffering from life-threatening diseases.»
New fund for VI Partners in fall 2019
VIP plans for a new fund in Fall 2019 to increase its firing power. This fund will primarily invest in Switzerland and early-stage companies. It will keep some reserves to pursue opportunities abroad, brought by the extensive network the partners of VIP have built over the last 20 years.
About VI Partners
VI Partners is the leading Swiss venture capital firm, providing promising healthcare and technology startup companies with capital, coaching and network access. Alain Nicod, Arnd Kaltofen, Daniel Gutenberg and Diego Braguglia are the four investment partners. Venture Incubator (VI) is a unique evergreen fund, created in 2000 by McKinsey & Company and the Swiss Federal Institute of Technology in Zürich (ETHZ). The CHF 101 million fund comes from 10 big corporates (ABB, Nestle, Novartis, Schindler, Hilti, Sulzer, Bühler, Suva, Zürcher Kantonalbank, Credit Suisse). Since its beginnings, VI Partners has invested in 48 startups in Switzerland, 28 of which were sold. Sales proceeds are reinvested in new companies.
vipartners.ch
This success story gets to another impressive chapter: During the last two months, VI Partners managed to successfully sell two participations:
• Nexthink: The shares owned by Venture Incubator were acquired in June 2019 in a secondary transaction by existing investors in the company.
• AMAL: The entire company was acquired by research-driven pharmaceutical company Boehringer Ingelheim for up to € 420 million in July 2019.
With the sales and transfers of the two companies, the fund realizes proceeds of up to CHF 105 million, depending on achievement of certain milestones. These results and developments demonstrate the commitment that Venture Incubator and VI Partners have to create meaningful companies in Switzerland.
Nexthink: 460 employees and 1,000 customers worldwide
Nexthink was launched as a result of a research project conducted at the prestigious Ecole Polytechnique Fédérale de Lausanne (EPFL) by Pedro Bados, Patrick Herzog and Vincent Bieri. The company has become the worldwide leader in the monitoring of employee experience for enterprises. Venture Incubator was the first institutional investor and the fund has been an active shareholder since the in initial investment. Today, Nexthink serves 1,000 customers worldwide (reaching over 7 million users), is growing 80% per annum and has attracted $130 million in financing.
Pedro Bados, co- founder and CEO of Nexthink, says: “It’s been a great experience with Alain and VI Partners who have supported Nexthink from the early stage until becoming a world-wide company. I would highly recommend any entrepreneur in Switzerland to consider them for their next venture.”
Alain Nicod, Managing Partner of VI Partners, says: «I am thankful to Pedro Bados, Patrick Herzog and Vincent Bieri that they have welcomed us as their first institutional investor in their newly born Nexthink SA. The road from the 5-person team I met then, to today’s business with 460 employees serving more than 7 million devices connected to their service, was incredibly exciting. I am particularly proud of having contributed to support the company’s growth not only with the initial money, but also with contacts, prospective customers, ideas, key management members and investors.»
AMAL: A unique technology platform to treat life-threatening diseases
AMAL was founded by Madiha Derouazi in 2012 as a spin-off from the University of Geneva, Switzerland. The start-up got financial backing from a syndicate of both corporate and institutional investors. AMAL’s proprietary technology platform KISIMA enables the assembly of three functional components into one patented fusion protein used as a vaccine: First, a proprietary cell-penetrating peptide for antigen delivery; second, a proprietary toll-like receptor (TLR) peptide agonist as an adjuvant; and third, a multi-antigenic cargo that can be tailored for specific tumors and other indications.
Madiha Derouazi, founder and CEO of AMAL, says: «I would like to warmly and sincerely thank VI Partners for their support to AMAL since our Series A investment back in March 2016. Their trust and commitment to AMAL as well as Diego Braguglia’s personal dedication and involvement have been instrumental to AMAL's success all along our journey which ends with this fantastic transaction."
Diego Braguglia, Managing Partner of VI Partners, comments: «I have rarely seen a company operating as cash efficient as AMAL. Madiha and her team can look back on an incredible journey, from bench to patient's bed sides in an unbelievably short period of time. I am deeply grateful to have been able to be part of this team and contribute along with the Venture Incubator investment to help and support patients suffering from life-threatening diseases.»
New fund for VI Partners in fall 2019
VIP plans for a new fund in Fall 2019 to increase its firing power. This fund will primarily invest in Switzerland and early-stage companies. It will keep some reserves to pursue opportunities abroad, brought by the extensive network the partners of VIP have built over the last 20 years.
About VI Partners
VI Partners is the leading Swiss venture capital firm, providing promising healthcare and technology startup companies with capital, coaching and network access. Alain Nicod, Arnd Kaltofen, Daniel Gutenberg and Diego Braguglia are the four investment partners. Venture Incubator (VI) is a unique evergreen fund, created in 2000 by McKinsey & Company and the Swiss Federal Institute of Technology in Zürich (ETHZ). The CHF 101 million fund comes from 10 big corporates (ABB, Nestle, Novartis, Schindler, Hilti, Sulzer, Bühler, Suva, Zürcher Kantonalbank, Credit Suisse). Since its beginnings, VI Partners has invested in 48 startups in Switzerland, 28 of which were sold. Sales proceeds are reinvested in new companies.
vipartners.ch
FINYEAR & CHAINEUM
Lisez gratuitement le quotidien Finyear & sa newsletter quotidienne.
Recevez chaque matin par mail la newsletter Finyear, une sélection quotidienne des meilleures infos et expertises en finance digitale, corporate finance & crypto finance.
Read for free The daily newspaper Finyear & its daily newsletter.
Receive the Finyear's newsletter every morning by email, a daily snapshot of the best news and expertise in digital finance, corporate finance & crypto finance.
------------------------
Chaineum :
Fondée en 2015, Chaineum est un cabinet de conseil en opérations de haut de bilan offrant une expertise de premier plan en matière d’ICO et STO, avec une vision stratégique orientée tant vers le métier de ses clients que sur la technologie blockchain. A ce titre, Chaineum a participé à la mise en œuvre de bonnes pratiques dans le secteur (ICO Charter, Security Token Network).
La division services blockchain de Chaineum, développe la technologie Chaineum Segment, une blockchain privée orientée objets.
About Chaineum:
Founded in 2015, Chaineum is a leading corporate finance advisory firm with a strong expertise in ICO and STO, and a strategic focus on both its clients' business and blockchain technology. As such, Chaineum paved the way in the implementation of certain best practices in this sector (ICO Charter, Security Token Network).
Chaineum's blockchain services division, is developing Chaineum Segment technology, an object-oriented private blockchain.
-------------------------
Recevez chaque matin par mail la newsletter Finyear, une sélection quotidienne des meilleures infos et expertises en finance digitale, corporate finance & crypto finance.
Read for free The daily newspaper Finyear & its daily newsletter.
Receive the Finyear's newsletter every morning by email, a daily snapshot of the best news and expertise in digital finance, corporate finance & crypto finance.
------------------------
Chaineum :
Fondée en 2015, Chaineum est un cabinet de conseil en opérations de haut de bilan offrant une expertise de premier plan en matière d’ICO et STO, avec une vision stratégique orientée tant vers le métier de ses clients que sur la technologie blockchain. A ce titre, Chaineum a participé à la mise en œuvre de bonnes pratiques dans le secteur (ICO Charter, Security Token Network).
La division services blockchain de Chaineum, développe la technologie Chaineum Segment, une blockchain privée orientée objets.
About Chaineum:
Founded in 2015, Chaineum is a leading corporate finance advisory firm with a strong expertise in ICO and STO, and a strategic focus on both its clients' business and blockchain technology. As such, Chaineum paved the way in the implementation of certain best practices in this sector (ICO Charter, Security Token Network).
Chaineum's blockchain services division, is developing Chaineum Segment technology, an object-oriented private blockchain.
-------------------------
No Offer, Solicitation, Investment Advice, or Recommendations
This website is for informational purposes only and does not constitute an offer to sell, a solicitation to buy, or a recommendation for any security, nor does it constitute an offer to provide investment advisory or other services by FINYEAR.
No reference to any specific security constitutes a recommendation to buy, sell or hold that security or any other security.
Nothing on this website shall be considered a solicitation or offer to buy or sell any security, future, option or other financial instrument or to offer or provide any investment advice or service to any person in any jurisdiction.
Nothing contained on the website constitutes investment advice or offers any opinion with respect to the suitability of any security, and the views expressed on this website should not be taken as advice to buy, sell or hold any security. In preparing the information contained in this website, we have not taken into account the investment needs, objectives and financial circumstances of any particular investor.
This information has no regard to the specific investment objectives, financial situation and particular needs of any specific recipient of this information and investments discussed may not be suitable for all investors.
Any views expressed on this website by us were prepared based upon the information available to us at the time such views were written. Changed or additional information could cause such views to change.
All information is subject to possible correction. Information may quickly become unreliable for various reasons, including changes in market conditions or economic circumstances.
No reference to any specific security constitutes a recommendation to buy, sell or hold that security or any other security.
Nothing on this website shall be considered a solicitation or offer to buy or sell any security, future, option or other financial instrument or to offer or provide any investment advice or service to any person in any jurisdiction.
Nothing contained on the website constitutes investment advice or offers any opinion with respect to the suitability of any security, and the views expressed on this website should not be taken as advice to buy, sell or hold any security. In preparing the information contained in this website, we have not taken into account the investment needs, objectives and financial circumstances of any particular investor.
This information has no regard to the specific investment objectives, financial situation and particular needs of any specific recipient of this information and investments discussed may not be suitable for all investors.
Any views expressed on this website by us were prepared based upon the information available to us at the time such views were written. Changed or additional information could cause such views to change.
All information is subject to possible correction. Information may quickly become unreliable for various reasons, including changes in market conditions or economic circumstances.
